KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) FCF Margin (2016 - 2025)

Regeneron Pharmaceuticals has reported FCF Margin over the past 17 years, most recently at 23.74% for Q4 2025.

  • Quarterly results put FCF Margin at 23.74% for Q4 2025, down 432.0% from a year ago — trailing twelve months through Dec 2025 was 28.45% (up 265.0% YoY), and the annual figure for FY2025 was 28.45%, up 265.0%.
  • FCF Margin for Q4 2025 was 23.74% at Regeneron Pharmaceuticals, down from 37.75% in the prior quarter.
  • Over the last five years, FCF Margin for REGN hit a ceiling of 3919.8% in Q1 2022 and a floor of 4.89% in Q2 2024.
  • Median FCF Margin over the past 5 years was 27.5% (2024), compared with a mean of 433.77%.
  • Biggest five-year swings in FCF Margin: skyrocketed 389632bps in 2022 and later tumbled -388219bps in 2023.
  • Regeneron Pharmaceuticals' FCF Margin stood at 1848.0% in 2021, then surged by 31bps to 2411.85% in 2022, then crashed by -99bps to 24.41% in 2023, then grew by 15bps to 28.06% in 2024, then dropped by -15bps to 23.74% in 2025.
  • The last three reported values for FCF Margin were 23.74% (Q4 2025), 37.75% (Q3 2025), and 25.18% (Q2 2025) per Business Quant data.